Funded Grants

Grants awarded in the current fiscal year and carried over from prior fiscal years.

PI Name Sort ascending	PI Organization	Title	Grant Number	Program Official
Yilmaz, Omer	Massachusetts Institute Of Technology United States	PROSPECT - Stem cell models	3OT2CA297570-01S1	Asad Umar, D.V.M., Ph.D.
Yendamuri, Saikrishna	Roswell Park Cancer Institute Corp United States	Metformin for chemoprevention of lung cancer in obese subjects at high risk	5R01CA255515-05	Malgorzata Wojtowicz, M.D.
Yeh, Jennifer M.	Boston Children'S Hospital United States	Can risk-reducing medications improve breast cancer prevention in childhood and adolescent cancer survivors? Comparative modeling to inform care	5R01CA261874-04	Eileen Dimond, R.N., M.S.
Yang, Wan	Columbia University Health Sciences United States	UNCOVER: underlying novel causes of onset of very early cancer research	5R01CA257971-05	Nicholas Hodges, Ph.D.
Yang, Qing	University Of Texas Med Br Galveston United States	The role of acute excitation of sensory neurons in the development of paclitaxel-induced peripheral neuropathy	5R01CA273001-02	Rachel Altshuler, Ph.D.
Yaghjyan, Lusine	University Of Florida United States	Stromal contributions to breast carcinogenesis	5R01CA277817-03	Christos Patriotis, Ph.D., M.Sc.
Xu, Chunhui	Emory University United States	High-throughput assessment of chemotherapy-induced cardiotoxicity in 3D human cardiomyocytes	1R21CA285254-01A1	Eileen Dimond, R.N., M.S.
Xu, Xiangxi Mike	University Of Miami School Of Medicine United States	Countering microtubule stabilization within hair follicles in ovarian cancer chemotherapy	5R01CA286527-02	Rachel Altshuler, Ph.D.
Wu, Yun	State University Of New York At Buffalo United States	Lung Cancer Early Detection and Immunotherapy Response Prediction and Monitoring with an Exo-PROS Liquid Biopsy Assay	4R01CA272827-04	Christos Patriotis, Ph.D., M.Sc.
Wright, Alexi A	Dana-Farber Cancer Inst United States	Randomized trial of REVITALIZE: A telehealth intervention to reduce fatigue interference among adults with advanced ovarian cancer on PARP inhibitors	5R01CA289547-02	Goli Samimi, Ph.D., M.P.H.